Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin

Journal of Interventional Cardiac Electrophysiology

Volumn 35, Issue 3, 2012, Pages 277-284

  Konduru, Sai V ^a   Cheema, Aamir A ^a   Jones, Philip ^a   Li, Yan ^a   Ramza, Brian ^a   Wimmer, Alan P ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Catheter ablation; Dabigatran; Heparin; Warfarin

Indexed keywords

DABIGATRAN; HEPARIN; WARFARIN;

ADULT; AGED; ANALYZER; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CATHETER ABLATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE TITRATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; COMORBIDITY; FEMALE; HEPARIN; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84869889734     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-012-9719-9     Document Type: Article

References (15)

1. Cappato, R., Calkins, H., Chen, S., Davies, W., Iesaka, Y., Kalman, J., et al. (2005). Worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation. Circulation, 111, 1100-1105.
2. Di Biase, L., Burkhardt, J. D., Mohanty, P., Sanchez, J., Horton, R., Gallinghouse, G. J., et al. (2010). Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation, 121(23), 2550-2556.
3. Gopinath, D., Lewis, W. R., Biase, L. D., & Natale, A. (2011). Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations. Journal of Cardiovascular Electrophysiology, 22(2), 236-239.
4. Hussein, A. A., Martin, D. O., Saliba, W., Patel, D., Karim, S., Batal, O., et al. (2009). Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm, 10, 1425-1429.
5. Oral, H., Chugh, A., Ozaydin, M., Good, E., Fortino, J., Sankara, S., et al. (2006). Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation, 114, 759-765.
6. Viles-Gonzalez, J. F.,&Mehta, D. (2011). Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation. Current Cardiology Reports, 13(1), 38-42.
7. Bruce, C. J., Friedman, P. A., Narayan, O., Munger, T. M., Hammill, S. C., Packer, D. L., et al. (2008). Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 22(3), 211-219.
8. Keane, D., Mansour, M., & Singh, J. (2004). Detection by intracardiac echocardiography of early formation of left atrial thrombus during pulmonary vein isolation. Europace, 6, 109-110.
9. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361, 1139-1151.
10. Eriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009). Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clinical Pharmacokinetics, 48(1), 1-22.
11. Kwak, J., Pak, H., Jang, J., Kim, S. K., Park, J. H., Choi, J., et al. (2010). Safety and convenience of continuous warfarin strategy during the periproceedural period in patients who underwent catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 21(6), 620-625.
12. Ryn, J., Stangier, J., Haertter, S., Liesenfeld, K., Wienen, W., Feuring, M., et al. (2010). Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis, 103, 1116-1127.
13. Laux, V., Perzborn, E., Heitmeier, S., von Degenfeld, G., Dittrich- Wengenroth, E., Buchmuller, A., et al. (2009). Direct inhibitors of coagulation proteins-The end of the heparin and low-molecularweight heparin era for anticoagulant therapy? Thrombosis and Haemostasis, 102(5), 892-899.
14. Liesenfeld, K. H., Schäfer, H. G., Trocóniz, I. F., Tillman, C., & Eriksson, B. I. (2006). Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. British Journal of Clinical Pharmacology, 62(5), 527-537.
15. Lakkireddy, D., Reddy, Y. M., Di Biase, L., Vanga, S. R., Santangeli, P., Swarup, V., et al. (2012). Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal of the American College of Cardiology, 59, 1168-1174.